SEARCH:
Print

Pipeline

VACCINES IN CLINICAL DEVELOPMENT
PRODUCT INDICATION DEVELOPMENT PHASE COMMERCIAL RIGHTS
    1 2 3 4  
INFECTIOUS DISEASES
IMVAMUNE liquid-frozen * Smallpox . . . . Bavarian Nordic
IMVAMUNE freeze-dried Smallpox . . . . Bavarian Nordic
MVA-BN RSV RSV . . . . Bavarian Nordic
MVA-BN Filo monovalent Ebola . . . . Janssen
MVA-BN Filo multivalent Ebola/Marburg . . . . Janssen
MVA-BN HPV + AdVac Chronic HPV infection Planned 2018 . . . Janssen
MVA-BN HIV + AdVac HIV-1 Planned 2018 . . . Janssen
MVA-BN HBV + AdVac Hepatitis B Preclinical Janssen
CANCER IMMUNOTHERAPY
CV301 + pembrolizumab Lung cancer . . . . Bavarian Nordic
CV301 + atezolizumab Bladder cancer . Planned 2018 . . Bavarian Nordic
CV301 + durvalumab Colorectal cancer . Planned 2018 . . Bavarian Nordic
CV301 + nivolumab Colorectal cancer . Planned 2018 . . Bavarian Nordic
BN-Brachyury Chordoma . Planned 2018 . . Bavarian Nordic
PROSTVAC combinations Prostate cancer . . . . Bristol-Myers Squibb
* Approved in the European Union under the trade name IMVANEX® and in Canada under the trade name IMVAMUNE®. Phase 3 completed in the United States. Filing of BLA is expected in 2018.